Short answer
UroGen Pharma Ltd. (URGN) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $51M (up 151.6% year over year) with net income of −$24M.
Q1 2026 key financials · XBRL
- Revenue
- $51M
- +151.6% YoY
- Net income
- −$24M
- +46.2% YoY
- Operating margin
- -39.8%
- Gross margin
- 91.9%
- EPS (diluted)
- −$0.47
- +48.9% YoY
Source: XBRL data from the UroGen Pharma Ltd. (URGN) Q1 2026 10-Q on SEC EDGAR. USD.
UroGen Pharma Ltd. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Zusduri promotion began late June 2025; permanent J-code effective January 1, 2026
- UGN-103 enrollment completed with 99 patients; three-month CR rate 77.8%
- UGN-104 Phase 3 enrollment expected to complete by end of 2026
- UGN-501 IND submission planned for second quarter 2026; Phase 1 trial targeted by end of 2026
Risk Factors
- New financing risk triggered by February 2026 loan refinancing: $200.0 million drawn, with $50.0 million available through June 30, 2027
- Financial leverage: Pharmakon loans carry fixed 8.25% interest and mature February 2031
- Liquidity risk: cash and marketable securities totaled $140.3 million at March 31, 2026, with $42.4 million remaining ATM capacity
- Commercial risk: ongoing Zusduri launch depends on physician and patient adoption despite limited market experience
- Regulatory risk: post-marketing safety data could force label changes or withdrawal of Jelmyto or Zusduri
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other UroGen Pharma Ltd. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.